Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT8SFV)

• Drug Name: 1-methyl-L-tryptophan Drug Info
• Synonyms: 1-L-MT; 1-LMT

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Preclinical	[1]

• Cross-matching ID:
  PubChem CID: 676159
  CAS Number: CAS 21339-55-9
  TTD Drug ID: DMT8SFV

Molecule-Related Drug Atlas

Drug(s) Targeting Indoleamine 2,3-dioxygenase 1 (IDO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[3]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[4]
BMS-986205	DM3MAYQ	Melanoma	2C30	Phase 3	[5]
INCB24360	DMIJGT9	Urothelial carcinoma	2C92.0	Phase 3	[6]
NLG8189	DM0798Z	Melanoma	2C30	Phase 2/3	[5]
DN1406131	DMQFX8R	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
HTI-1090	DMI4TEC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
KHK2455	DMLSUQ8	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
LY3381916	DMONZ1L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
PF-06840003	DMOX6EJ	Glioma	2A00.0	Phase 1	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Indoleamine 2,3-dioxygenase 1 (IDO1)	TTZJYKH	I23O1_HUMAN	Inhibitor	[2]

References

• [1] Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
• [2] Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013 Nov 14;56(21):8321-31.
• [3] Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
• [4] Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Incyte. Product Development Pipeline.
• [7] ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
• [8] Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)